Why do so many companies in the Life Sciences make endless losses in the name of Research and Development? The matter of clinical trials has not only become a bit of a cliché, but holds out the sword of potential losses over investor heads. That must be a principal reason for Forbes magazine selecting Neogen Corporation (NASDAQ:NEOG) 5 times in the last 7 years as the best of small companies in the United States. This company has a stream of proprietary products; it also has a solid track record of steady quarterly growth in 57 of the last 62 quarters, and profitable operations for over 13 years.
Durable organization, sound management processes, and an integrated approach to business, distinguish Neogen Corporation (NASDAQ:NEOG) from many of its competitors. An extensive sales team, global operations, and efficient logistics focus the company as much on existing product lines as working on new discoveries and ideas. The management has also displayed consistent strategic insight, making judicious acquisitions and signing creative collaboration agreements that have created economic and technical moats around key customers.
Food safety has always been a widespread public concern, and liberal trade exchanges with other countries have only accentuated the daily need to check all edible material for pathogenic contamination and biological decay. Neogen Corporation (NASDAQ:NEOG) has done well to extend its product lines to veterinary applications, because it has opened an entirely new line of revenue for substantial fixed expenses of research, sourcing, and manufacturing. The company has an exciting pipe line of new products and services, in addition to superior prospects for its existing brands.
Let us hear your thoughts below: